---
title: "Bristol Myers Squibb (BMY) Doubles MRD‑Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300139432.md"
description: "Bristol Myers Squibb reported that in the Phase 3 EXCALIBER-RRMM trial, ZENBEXUS with daratumumab/dexamethasone achieved a 41.1% MRD-negative complete response rate versus 20.7% for DVd (p"
datetime: "2026-09-25T14:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300139432.md)
  - [en](https://longbridge.com/en/news/300139432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300139432.md)
generator: "portal-rs"
---

# Bristol Myers Squibb (BMY) Doubles MRD‑Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM

Bristol Myers Squibb reported EXCALIBER-RRMM showed ZENBEXUS with daratumumab/dexamethasone achieved 41.1% MRD‑negative CR vs 20.7% with DVd (p<0.0001) at 15.7 months’ median follow-up in 420 patients. PFS, the co‑primary endpoint, is still being evaluated.

**Material Details**

| # | Detail                                       | AI Analyst View                                                                                      |
| - | -------------------------------------------- | ---------------------------------------------------------------------------------------------------- |
| 1 | MRD‑neg CR 41.1% vs 20.7% (p<0.0001)         | Statistically significant efficacy signal supports accelerated approval path and potential adoption. |
| 2 | ORR 88.9% vs 76.1%                           | Higher response rates bolster clinical competitiveness vs standard DVd.                              |
| 3 | CR or better 45.9% vs 24.9%                  | Deeper responses can translate into longer disease control if sustained.                             |
| 4 | Safety: neutropenia Grade 3/4 84.3% vs 11.3% | High hematologic toxicity may limit use; requires management resources.                              |
| 5 | Lower neuropathy: 12.3% vs 42.6%             | Less neuropathy vs bortezomib regimen may favor ZENBEXUS in practice.                                |
| 6 | PFS co‑primary ongoing (n=800)               | Confirmatory PFS readout is key for full approval and broader uptake.                                |

**Context by AI Analyst**

This is a mid‑cycle clinical validation step, adding quantitative efficacy data after prior accelerated approval based on MRD‑neg CR. For a larger catalyst, the confirmatory PFS co‑primary endpoint must show superiority and support conversion to full approval.

Based on the original press release from Bristol Myers Squibb distributed by BusinessWire.

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by BusinessWire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma](https://longbridge.com/en/news/300139167.md)
- [Bristol Myers Squibb secures expanded US approval for Camzyos](https://longbridge.com/en/news/300671144.md)
- [FDA grants accelerated approval to Bristol Myers Squibb’s ZENBEXUS for relapsed multiple myeloma combo use](https://longbridge.com/en/news/295848217.md)
- [Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment](https://longbridge.com/en/news/295957550.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**